source
- FDA issues three new guidances to expand eligibility criteria for cancer trialsThe FDA's Oncology Center of Excellence has released three final guidance documents aimed at widening the pool of patients who can enroll in oncology clinical trials. The guidances focus on three…
- MapLight’s schizophrenia pill hits primary endpoint but falls short of challenging BMS’s CobenfyMapLight Therapeutics reported results from its Phase 2 ZEPHYR trial of the oral muscarinic agonist ML-007C-MA in schizophrenia. The trial met its primary endpoint, showing a statistically signifi…